Ohcanbohtosat - Vera Bril

Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis Dahkki Vera Bril, Johannes Lampe, Nichola Cooper, Peter Kiessling, Ann Gardulf

Connect to this object online.

Long-Term Treatment With Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Suppresses Diabetic Neuropathy and Cataract Formation in Rats Dahkki Takafumi Matsumoto, Yoshiyuki Ono, Akemi Kuromiya, Kaoru Toyosawa, Yoshinaka Ueda, Vera Bril

Connect to this object online.

Improvement of Motor Nerve Conduction Velocity in Diabetic Rats Requires Normalization of the Polyol Pathway Metabolites Flux Dahkki Takafumi Matsumoto, Yoshiyuki Ono, Masuo Kurono, Akemi Kuromiya, Keiji Nakamura, Vera Bril

Connect to this object online.

Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Reduces Sorbitol Levels and Improves Motor Nerve Conduction Velocity in Streptozotocin-Diabetic Rats Dahkki Takafumi Matsumoto, Yoshiyuki Ono, Masuo Kurono, Akemi Kuromiya, Keiji Nakamura, Vera Bril

Connect to this object online.

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy Dahkki Michael A. Tortorici, Theresa Yuraszeck, David Cornblath, Vera Bril, Hans‐Peter Hartung, Gen Sobue, Richard A. Lewis, Ingemar S. J. Merkies, John‐Philip Lawo, Michaela Praus, Billie L. Durn, Orell Mielke, Xuewen Ma, Petra Jauslin, Marc Pfister, Ivo N. vanSchaik, the PATH study group

Connect to this object online.